The Landscape of Chromosome Instability in Breast Cancers and Associations with the Tumor Mutation Burden: An Analysis of Data from TCGA

References

• Voutsadakis IA. Clinical implications of chromosomal instability (CIN) and kinetochore abnormalities in breast cancers. Mol Diagn Ther. 2019;23(6):707–21. doi:10.1007/s40291-019-00420-2.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Burrell RA, Endesfelder D, Novelli MR, Swanton C. Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep. 2012;13(6):528–38. doi:10.1038/embor.2012.61.
   PubMed Web of Science ®Google Scholar
• Danielsen HE, Pradhan M, Novelli M. Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era. Nat Rev Clin Oncol. 2016;13(5):291–304. doi:10.1038/nrclinonc.2015.208.
   PubMed Web of Science ®Google Scholar
• Xu J, Huang L, Li J. DNA aneuploidy and breast cancer: a meta-analysis of 141,163 cases. Oncotarget. 2016;7(37):60218–29. doi:10.18632/oncotarget.11130.
   PubMedGoogle Scholar
• Szász AM, Li Q, Eklund AC, Sztupinszki Z, Rowan A, Tőkés AM, et al. The CIN4 chromosomal instability qPCR classifier defines tumor aneuploidy and stratifies outcome in grade 2 breast cancer. PLoS ONE. 2013;8(2):e56707. doi:10.1371/journal.pone.0056707.
   PubMed Web of Science ®Google Scholar
• Pfister K, Pipka JL, Chiang C, Liu Y, Clark RA, Keller R, et al. Identification of drivers of aneuploidy in breast tumors. Cell Rep. 2018;23(9):2758–69. doi:10.1016/j.celrep.2018.04.102.
   PubMed Web of Science ®Google Scholar
• Stopsack KH, Whittaker CA, Gerke TA, Loda M, Kantoff PW, Mucci LA, et al. Aneuploidy drives lethal progression in prostate cancer. Proc Natl Acad Sci U S A. 2019;116(23):11390–5. doi:10.1073/pnas.1902645116.
   PubMed Web of Science ®Google Scholar
• Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, et al., Cancer Genome Atlas Research Network. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell. 2018;33(4):676–89. doi:10.1016/j.ccell.2018.03.007.
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490:61–70.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4. doi:10.1158/2159-8290.CD-12-0095.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6:269.
   Web of Science ®Google Scholar
• Colli LM, Machiela MJ, Myers TA, Jessop L, Yu K, Chanock SJ, et al. Burden of nonsynonymous mutations among TCGA cancers and candidate immune checkpoint inhibitor responses. Cancer Res. 2016;76(13):3767–72. doi:10.1158/0008-5472.CAN-16-0170.
   PubMed Web of Science ®Google Scholar
• Voutsadakis IA. Polymerase epsilon mutations and concomitant β2-microglobulin mutations in cancer. Gene. 2018;647:31–8. doi:10.1016/j.gene.2018.01.030.
   PubMed Web of Science ®Google Scholar
• Veneris JT, Lee EK, Goebel EA, Nucci MR, Lindeman N, Horowitz NS, et al. Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. Gynecol Oncol. 2019;153(3):471–8. doi:10.1016/j.ygyno.2019.03.247.
   PubMed Web of Science ®Google Scholar
• Tang YC, Williams BR, Siegel JJ, Amon A. Identification of aneuploidy-selective antiproliferation compounds. Cell. 2011;144(4):499–512. doi:10.1016/j.cell.2011.01.017.
   PubMed Web of Science ®Google Scholar
• Manchado E, Malumbres M. Targeting aneuploidy for cancer therapy. Cell. 2011;144(4):465–6. doi:10.1016/j.cell.2011.01.037.
   PubMed Web of Science ®Google Scholar
• Tang YC, Yuwen H, Wang K, Bruno PM, Bullock K, Deik A, et al. Aneuploid cell survival relies upon sphingolipid homeostasis. Cancer Res. 2017;77(19):5272–86. doi:10.1158/0008-5472.CAN-17-0049.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA, Pritchard KI, et al. Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, Human Epidermal Growth Factor Receptor 2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol. 2016;34(5):419–26. doi:10.1200/JCO.2014.60.1971.
   PubMed Web of Science ®Google Scholar
• Voutsadakis IA. High tumor mutation burden and other immunotherapy response predictors in breast cancers: associations and therapeutic opportunities. Target Oncol. 2020;15(1):127–38. doi:10.1007/s11523-019-00689-7.
   PubMed Web of Science ®Google Scholar
• Oltmann J, Heselmeyer-Haddad K, Hernandez LS, Meyer R, Torres I, Hu Y, et al. Aneuploidy, TP53 mutation, and amplification of MYC correlate with increased intratumor heterogeneity and poor prognosis of breast cancer patients. Genes Chromosomes Cancer. 2018;57(4):165–75. doi:10.1002/gcc.22515.
   PubMed Web of Science ®Google Scholar
• Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al., METABRIC Group. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–52. doi:10.1038/nature10983.
   PubMed Web of Science ®Google Scholar
• Pereira B, Chin SF, Rueda OM, Vollan HKM, Provenzano E, Bardwell HA, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479. doi:10.1038/ncomms11479.
   PubMed Web of Science ®Google Scholar
• Russnes HG, Lingjaerde OC, Børresen-Dale AL, Caldas C. Breast cancer molecular stratification: from intrinsic subtypes to integrative clusters. Am J Pathol. 2017;187(10):2152–62. doi:10.1016/j.ajpath.2017.04.022.
   PubMed Web of Science ®Google Scholar
• Aylon Y, Oren M. p53: guardian of ploidy. Mol Oncol. 2011;5(4):315–23. doi:10.1016/j.molonc.2011.07.007.
   PubMed Web of Science ®Google Scholar
• Burds AA, Schulze Lutum A, Sorger PK. Generating chromosome instability through the simultaneous deletion of Mad2 and p53. Proc Natl Acad Sci U S A. 2005;102(32):11296–301. doi:10.1073/pnas.0505053102.
   PubMed Web of Science ®Google Scholar
• Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1 mutations. Pathology. 2013;45(2):116–26. doi:10.1097/PAT.0b013e32835d0efb.
   PubMed Web of Science ®Google Scholar
• Smith CL, Migliaccio I, Chaubal V, Wu MF, Pace MC, Hartmaier R, et al. Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence. Breast Cancer Res Treat. 2012;136(1):253–65. doi:10.1007/s10549-012-2262-7.
   PubMed Web of Science ®Google Scholar
• Légaré S, Basik M. Minireview: the link between ERα corepressors and histone deacetylases in tamoxifen resistance in breast cancer. Mol Endocrinol. 2016;30(9):965–76. doi:10.1210/me.2016-1072.
   PubMedGoogle Scholar
• Smid M, Hoes M, Sieuwerts AM, Sleijfer S, Zhang Y, Wang Y, et al. Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. Breast Cancer Res Treat. 2011;128(1):23–30. doi:10.1007/s10549-010-1026-5.
   PubMed Web of Science ®Google Scholar
• Davies V, Voutsadakis IA. Amplification of chromosome 17 centromere (CEP17) in breast cancer patients with a result of HER2 2± by Immunohistochemistry. Cancer Invest. 2020;38(2):94–101. doi:10.1080/07357907.2020.1720223.
   PubMed Web of Science ®Google Scholar
• Halilovic A, Verweij DI, Simons A, Stevens-Kroef MJPL, Vermeulen S, Elsink J, et al. HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study. Sci Rep. 2019;9(1):11679. doi:10.1038/s41598-019-48212-2.
   PubMedGoogle Scholar
• Lee K, Kim HJ, Jang MH, Lee S, Ahn S, Park SY, et al. Centromere 17 copy number gain reflects chromosomal instability in breast cancer. Sci Rep. 2019;9(1):17968. doi:10.1038/s41598-019-54471-w.
   PubMedGoogle Scholar